ReviewWorld journal of gastrointestinal endoscopy2025
Evaluating the prognostic efficacy of biomarkers in pancreatic cyst fluid.
Review in World journal of gastrointestinal endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluating the prognostic significance of biomarkers in pancreatic cyst fluid, accessed through endoscopic ultrasound-guided fine-needle aspiration, is essential for improving the clinical management of pancreatic cysts. This review synthesizes the evidence from studies published on the field in the last years, focusing on the accuracy and clinical utility of biomarkers such as carcinoembryonic antigen, intracystic glucose, and novel genetic markers including DNA mutation analysis. Our findings indicate that elevated carcinoembryonic antigen levels and decreased intra-cystic glucose levels are strongly associated with mucinous cysts which carry a higher malignancy risk, while DNA mutation analysis has shown increased predictive accuracy for identifying malignant transformations. Integrating these biomarkers with imaging techniques enhances risk stratification and can significantly influence therapeutic decisions. The review highlights the need for standardization of biomarker assays and further validation of biomarker panels to refine their prognostic value in clinical settings, ultimately aiding in the tailored management of patients with pancreatic cysts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.